PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for 225 AcAc-PSMA Radiopharmaceutical Therapy

225Ac-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) has emerged as a promising treatment option in advanced metastatic castration-resistant prostate cancer. We aimed to identify predictors for outcome including established clinical and PSMA-directed imaging parameters at baseline. Methods: Twenty-six patients with metastatic castration-resistant prostate cancer who were receiving 225AcAc-PSMA-I defined as PSMA-TV divided by SUVmean). PET parameters were then correlated with the relative prostate-specific antigen (PSA) change after 2 cycles of 225AcAc-PSMA-I defined as a PSA increase of more than 25% or PD according to RECIP 1.0) after 2 cycles, progression-free survival (PFS), and overall survival (OS) were explored. Results: SUVmax (r = -0.42, P = 0.031) and SUVmean (r = -0.4, P = 0.046) correlated significantly with PSA change after 2 cycles, but PSMA-TV (P = 0.51) and PSMA-TLQ (P = 0.83) did not. Eleven patients (42%) demonstrated early PD. SUVmax (odds ratio, 0.769; P = 0.032) and SUVmean (odds ratio, 0.427; P = 0.041) were predictive for early PD. SUVmean emerged as the strongest predictor for prolonged PFS (hazard ratio HR, 0.501; P = 0.006) with SUVmax also trending toward significance (HR, 0.914; P = 0.054). Patients with a high SUVmean achieved a longer median PFS of 134 d compared with 39 d in patients with low SUVmean (HR, 0.369; P = 0.041). PSMA-TLQ (HR, 1.007; P = 0.027) and PSMA-TV (HR, 1.001; P = 0.037) were predictive for OS. Patients with a low PSMA-TLQ (reflecting low PSMA-TV in combination with high SUVmean) achieved a longer median OS of 375 d compared with 148 d in patients with high PSMA-TLQ (HR, 2.84; P = 0.043). Conclusion: In patients scheduled for 225AcAc-PSMA-I&T RPT, SUVmean on pretherapeutic 18FF-PSMA-1007 PET/CT is predictive for early treatment response by identifying individuals prone to early PD and shorter PFS. In addition, PSMA-TLQ is associated with OS. As such, pretherapeutic PSMA PET-based quantification may optimize patient selection for targeted α-RPT.